Commenced buildout of dedicated HPC data halls and remain on track to deliver 72.5 MW of gross HPC hosting infrastructure to Core42 in 2025. Initiated process to secure additional HPC customers; targeting 200–250 MW operational by year-end 2026. Energized Miner Building 5, bringing total capacity to 245 MW and increasing hashrate to 12.2 EH/s, up 52.5% year-over-year. Self-mining capacity increased 52.5% year-over-year to 12.2 EH/s. Held $219.6 million in cash and bitcoin holdings as of March 31, 2025. Repu ...

Core Viewpoint - AMC Networks Inc. reported a decline in financial performance for the first quarter of 2025, with significant decreases in net revenues, operating income, and earnings per share, while maintaining a focus on expanding its streaming services and content offerings [2][5][6]. Financial Highlights - Net revenues for Q1 2025 were $555.2 million, down 6.9% from $596.5 million in Q1 2024 [5]. - Operating income decreased by 41.7% to $64.2 million from $110.2 million year-over-year [5]. - Adjusted operating income fell 29.9% to $104.5 million compared to $149.1 million in the previous year [5]. - Diluted earnings per share (EPS) dropped 67.0% to $0.34 from $1.03, while adjusted EPS decreased 55.2% to $0.52 from $1.16 [5]. - Free cash flow was reported at $94.2 million, a decline of 34.7% from $144.1 million in Q1 2024 [5]. Operational Highlights - The company launched ad-supported AMC+ for Charter customers and expanded its FAST channels business [6]. - "Dark Winds" returned for its third season with approximately 2.2 million viewers on premiere night, leading to increased AMC+ subscriber acquisition [6]. - The Anne Rice Immortal Universe continues to gain momentum with new series launches and renewals [6]. - AMC Networks is enhancing its advertising opportunities, particularly in the horror genre, with the upcoming ad-supported launch of Shudder [6]. Segment Results - Domestic operations reported net revenues of $524.2 million, a decrease of 7.2% from $486.3 million in Q1 2024 [7]. - International segment revenues were $75.6 million, down 7.5% from $69.9 million year-over-year [8]. - Subscription revenues in domestic operations decreased by 3% to $313 million, while streaming revenues increased by 8% to $157 million [9]. Changes in Subscriber Reporting - The company updated its definition of "streaming subscribers" to include only those who register on an a la carte basis, resulting in a slight decline in reported subscribers to 10.2 million as of March 31, 2025, compared to 10.4 million at the end of 2024 [9][11]. Stock Repurchase Program - The Board of Directors authorized a stock repurchase program of up to $1.5 billion, with $135 million remaining for repurchase as of March 31, 2025 [18].

NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating inc ...

FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Mee ...

MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to report continued operational progress at its Zgounder Silver Mine, driven by a strong mine ramp up, exceptional mill performance, a clear path to improve recovery, and solid April production. April Production Metrics Production Metrics Q1-2024Q1-2025April 2025Silver productionoz366,3621,068,652345,550Tonnage processedkt81,331<td style="border-top: solid black 1pt ; border-bot ...

– Q1 revenue of $24.5 million increased 1.9% year-over-year, in line with expectations for Vireo’s established markets – – Merger Transactions expected to begin closing in Q2 and further strengthen profitability profile – MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in summary form with supporting commentary and ...

MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) -- Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced the voting results from its Annual General Meeting of Shareholders held on Thursday May 8, 2025. Voting Results: A total of 12,310,101 common shares were voted at the meeting representing 50.12% of all outstanding shares. Shareholders voted in favour of the election of all ...

Management to host investor conference call today, May 9th, at 8:30am ETMIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prim ...

Core Insights - Kymera Therapeutics is advancing its first-in-class pipeline aimed at treating complex immuno-inflammatory diseases, with significant progress expected in the near term [2] - The company has completed the Phase 1 healthy volunteer trial for KT-621 and initiated the KT-621 BroADen Phase 1b trial in atopic dermatitis, with data expected in late 2025 [1][2][7] - Kymera has introduced KT-579, an oral IRF5 degrader program, which is set to enter Phase 1 clinical trials in early 2026 [1][4] - A strategic decision was made to not advance KT-295 into further clinical development, allowing for a focus on the STAT6 program and extending the cash runway into the first half of 2028 [1][2][16] Business Highlights - The KT-621 program targets Th2 inflammation and has shown dupilumab-like activity in preclinical studies, with potential applications for over 130 million patients globally suffering from Th2 diseases [3] - KT-579 is positioned as a novel mechanism for treating diseases with high unmet needs, such as lupus and rheumatoid arthritis, and is expected to enter clinical testing in early 2026 [4] - Ongoing Phase 2b trials for KT-474 in partnership with Sanofi are expected to complete in 2026, further validating Kymera's innovative approach to oral degrader medicines [8] Financial Results - Collaboration revenues for Q1 2025 were $22.1 million, a significant increase from $10.3 million in Q1 2024, primarily due to the Sanofi collaboration [9] - Research and development expenses rose to $80.3 million in Q1 2025 from $48.8 million in Q1 2024, reflecting increased investment in the STAT6 and TYK2 programs [10] - The net loss for Q1 2025 was $65.6 million, compared to $48.6 million in Q1 2024, with cash reserves of $775 million expected to sustain operations into the first half of 2028 [12][22]

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to del ...